https://www.businesswire.com/news/home/20190401005993/en/

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 2, 2019--Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that it closed a $40 million Series D financing. New investor Medicxi led the round, with current investors also participating.

The Company plans to use the proceeds from the Series D financing to support the late stage clinical development of their lead asset, light-activated AU-011, for the treatment of primary choroidal melanoma.